In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Mesoblast Ltd (MESO), with a price target of $16. The company’s shares closed on Friday at $4.70.
McCarthy commented:
“Mesoblast announced that the ongoing phase 3 trial for MPC-150-IM (Revascor, allogeneic cell therapy) in advanced heart failure has completed enrollment with N=570 patients across 55 centers in North America.”
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.6% and a 23.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $17.75.
See today’s analyst top recommended stocks >>
Based on Mesoblast Ltd’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.46 million. In comparison, last year the company had a net profit of $13.72 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.
